The ability of EIAV to persistently infect horses in the face of a profound immune response by the host makes it a potentially devastating disease for the horse population of the United States. Its ability to evade host immune defenses by lying dormant in apparently healthy animals and by rapidly changing its antigenic determinants is proving to be a major obstacle to vaccine development. Because most infected horses appear clinically normal and a large proportion of horses in this country remain untested, the virus is not likely to be eradicated in the near future. Yet, for the same reason, because most horses infected with EIAV appear clinically normal, there is a tendency for the horse industry to become complacent in its efforts to control the virus. The cooperation of horse owners, veterinarians, and regulatory officials is necessary to keep the threat of EIA in check in the United States.